Table 3.

—Results of Multivariate Analysis^a of Sex-Specific RHC, MRI, and Other Treatment Outcome Parameter Changes Compared With Baseline

Parameter	Difference for Men vs Women in Follow-up Measure After Adjustment for Baseline and Confounders	95% CI	P Value
NT-proBNP, ng/L	+1,385	+482 to +2,288	< .01
6MWD, m	−70	−127 to −12	.02
Creatinine, mmol/L	+14	+3 to +25	.01
GFR, mL/min	−6	−13 to 0	.05
WHO FC	+1.9	+0.9 to +3.0	< .001
Heart rate, beats/min	+5	−7 to +17	.42
RAP, mm Hg	+2	−1 to +6	.25
mean PAP, mm Hg	+2	−8 to +11	.73
CO, L/min	+0.0	−1 to +1	.99
Stroke volume, mL	−7	−24 to +11	.45
PVR, dyn × s × cm5	−35	−337 to +267	.82
RVEF, %	−7.2	−13 to −1	.02
RVEDV, mL	−0.4	−19 to +18	.97
RVESV, mL	+5.2	−13 to +23	.58
RVSV, mL	−9.5	−19 to 0	.04
RV mass, g	+3.8	−13 to +21	.67
RV mass/RVEDV, g/mL	+0.09	−0.05 to +0.24	.22

^aMultivariate analysis results corrected for potential confounding by age, weight, height, number of comorbidities, baseline RVEF, GFR, PVR, WHO FC, and type of PAH-specific medical therapy initiated. See Table 1 legend for expansion of abbreviations.